S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:ICCC

ImmuCell (ICCC) Competitors

$5.09
-0.05 (-0.97%)
(As of 06/6/2023 ET)
Compare
Today's Range
$5.06
$5.12
50-Day Range
$4.64
$5.35
52-Week Range
$4.26
$9.60
Volume
2,378 shs
Average Volume
7,084 shs
Market Capitalization
$39.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ICCC vs. NYMX, TRIB, AWH, OCX, BMRA, CDIO, MYMD, TKNO, ACHV, and PLAG

Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Aspira Women's Health (AWH), OncoCyte (OCX), Biomerica (BMRA), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Planet Green (PLAG). These companies are all part of the "medical" sector.

ImmuCell vs.

ImmuCell (NASDAQ:ICCC) and Nymox Pharmaceutical (NASDAQ:NYMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.

12.6% of ImmuCell shares are owned by institutional investors. Comparatively, 0.8% of Nymox Pharmaceutical shares are owned by institutional investors. 6.3% of ImmuCell shares are owned by insiders. Comparatively, 54.0% of Nymox Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmuCell
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nymox Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, Nymox Pharmaceutical had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Nymox Pharmaceutical and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 0.00 equaled Nymox Pharmaceutical's average media sentiment score.

Company Overall Sentiment
ImmuCell Neutral
Nymox Pharmaceutical Neutral

Nymox Pharmaceutical has a net margin of 0.00% compared to ImmuCell's net margin of -33.23%. ImmuCell's return on equity of -17.30% beat Nymox Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuCell -33.23% -17.30% -11.80%
Nymox Pharmaceutical N/A -1,589.50% -117.25%

ImmuCell has higher revenue and earnings than Nymox Pharmaceutical. Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than ImmuCell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuCell$18.57 million2.12-$2.49 million-$0.69-7.38
Nymox PharmaceuticalN/AN/A-$6.58 million-$0.04-10.19

Nymox Pharmaceutical received 29 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 51.72% of users gave Nymox Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
ImmuCellOutperform Votes
121
73.33%
Underperform Votes
44
26.67%
Nymox PharmaceuticalOutperform Votes
150
51.72%
Underperform Votes
140
48.28%

ImmuCell has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Nymox Pharmaceutical has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Summary

ImmuCell beats Nymox Pharmaceutical on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICCC vs. The Competition

MetricImmuCellDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$39.82M$2.34B$4.54B$6.29B
Dividend YieldN/A0.79%5.93%6.49%
P/E Ratio-7.3841.50126.6213.66
Price / Sales2.12662.383,622.2596.13
Price / Cash39,820.2737.6322.0376.28
Price / Book1.306.004.735.39
Net Income-$2.49M$28.14M$117.01M$192.60M
7 Day Performance6.71%1.09%4.55%4.21%
1 Month Performance3.88%0.12%2.63%5.13%
1 Year Performance-38.97%-16.61%12.34%1.30%

ImmuCell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NYMX
Nymox Pharmaceutical
0 of 5 stars
$0.45
+9.8%
N/A+7.3%$40.72MN/A-11.253
TRIB
Trinity Biotech
1.452 of 5 stars
$0.90
-2.2%
N/A-30.4%$34.30M$74.78M-0.70543Gap Down
AWH
Aspira Women's Health
1.6637 of 5 stars
$3.29
-6.0%
$30.00
+811.9%
-68.2%$27.41M$8.18M-0.25106
OCX
OncoCyte
2.291 of 5 stars
$0.22
+4.7%
$1.11
+400.9%
N/A$26.49M$960,000.000.00N/A
BMRA
Biomerica
0 of 5 stars
$1.54
flat
N/A-65.8%$25.89M$18.87M-2.8566
CDIO
Cardio Diagnostics
1.9939 of 5 stars
$1.54
+4.8%
$8.00
+419.5%
N/A$14.94MN/A0.00N/AGap Down
MYMD
MyMD Pharmaceuticals
0 of 5 stars
$1.83
-15.7%
N/A-44.5%$72.23MN/A-5.086Positive News
TKNO
Alpha Teknova
2.4535 of 5 stars
$3.79
+14.2%
$9.33
+146.3%
-52.2%$106.95M$41.42M-2.11237Positive News
ACHV
Achieve Life Sciences
2.034 of 5 stars
$6.24
-0.6%
$18.50
+196.5%
-6.0%$112.57MN/A-1.6616
PLAG
Planet Green
0 of 5 stars
$0.54
flat
N/A-40.9%$39.21M$44.76M0.00148High Trading Volume

Related Companies and Tools

This page (NASDAQ:ICCC) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -